Immediate Impact
70 standout
Citing Papers
Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Works of Sherry Li being referenced
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Sherry Li | 497 | 180 | 400 | 275 | 16 | 663 | |
| Stéphanie Deudon | 483 | 174 | 472 | 355 | 10 | 765 | |
| G. Jeannin | 530 | 161 | 454 | 400 | 21 | 818 | |
| Adnan Hasanovic | 498 | 254 | 315 | 239 | 16 | 657 | |
| Anne‐Claire Voegeli | 448 | 151 | 346 | 295 | 25 | 742 | |
| Robert C. Whorf | 467 | 199 | 410 | 343 | 20 | 776 | |
| Robin Wiltshire | 702 | 147 | 546 | 284 | 17 | 803 | |
| Lorin A. Ferris | 496 | 153 | 373 | 243 | 10 | 594 | |
| Mark R. Olsen | 579 | 167 | 410 | 254 | 20 | 757 | |
| Hao-Ran Zhai | 529 | 231 | 593 | 239 | 14 | 821 | |
| Leila Dardaei | 338 | 155 | 275 | 321 | 13 | 607 |
All Works
Loading papers...